Repeat PSA Screening for Virulent Prostate Cancer


Reference #: 01136

The University of South Carolina is offering licensing opportunities for an improved method of detecting high-risk prostate cancer that is able to distinguish it form non-virulent cancers as well as other conditions associated with elevated levels of prostate-specific antigens.

Invention Description:

The subject invention uses available repeat prostate-specific antigen (PSA) measures from the NCI-funded Prostate Lung Colorectal and Ovarian Cancer Screening Trial (PLCO) to predict subsequent diagnosis of clinically significant prostate cancer.

Potential Applications:

· Detection of virulent (i.e., high-risk, clinically relevant) prostate cancer using PSA alone or in combination with other screening methods

Advantages and Benefits:

· Distinguishes virulent prostate cancer from other prostate-related conditions that may be associated with elevated PSA concentration in blood


Prostate cancer is the most common cancer in the United States and the second leading cause of cancer deaths among men. It is generally a lower-risk cancer for which the treatment is often worse than the disease. The increased detection of low-risk prostate cancer based on PSA screenings is the foundation of the controversy that has  led to recommendations against screening.  Essentially, the current problems can be summarized as either over-treatment of indolent, low-risk disease that if left untreated has little chance of harming the patient but whose treatment can cause great harm ranging from infections to incontinence; or under-treating virulent, high-risk disease which is likely to be fatal. This technology is an effective way to detect life-threatening prostate cancer and distinguish it from other conditions associated with elevated PSA.

Patent Information:
Health Sciences
For Information, Contact:
Technology Commercialization
University of South Carolina
James Hebert
Azza Shoaibi
© 2024. All Rights Reserved. Powered by Inteum